Svb Leerink Initiates Coverage on Avedro (AVDR)

Svb Leerink started coverage on shares of Avedro (NASDAQ:AVDR) in a research note released on Monday, Marketbeat.com reports. The firm issued an outperform rating and a $20.00 price target on the stock. Svb Leerink also issued estimates for Avedro’s Q1 2019 earnings at ($0.98) EPS, Q2 2019 earnings at ($0.54) EPS, Q3 2019 earnings at ($0.51) EPS, Q4 2019 earnings at ($0.44) EPS, FY2019 earnings at ($2.28) EPS, Q1 2020 earnings at ($0.52) EPS, Q2 2020 earnings at ($0.46) EPS, Q3 2020 earnings at ($0.37) EPS, Q4 2020 earnings at ($0.36) EPS, FY2020 earnings at ($1.70) EPS, FY2021 earnings at ($1.02) EPS, FY2022 earnings at ($0.06) EPS and FY2023 earnings at $0.79 EPS.

Other research analysts also recently issued research reports about the stock. Cowen started coverage on shares of Avedro in a research note on Monday. They issued an outperform rating and a $20.00 price target for the company. Leerink Swann started coverage on shares of Avedro in a research note on Monday. They issued an outperform rating and a $20.00 price target for the company. Finally, JPMorgan Chase & Co. started coverage on shares of Avedro in a research note on Monday. They issued an overweight rating and a $16.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, Avedro presently has an average rating of Buy and a consensus price target of $19.40.

Shares of Avedro stock opened at $12.74 on Monday. Avedro has a 52-week low of $10.75 and a 52-week high of $13.65.



In related news, Director Gilbert H. Kliman acquired 25,000 shares of Avedro stock in a transaction dated Tuesday, February 19th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $350,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

About Avedro

Avedro, Inc, an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations.

Featured Story: Buy-Side Analysts

Analyst Recommendations for Avedro (NASDAQ:AVDR)

Receive News & Ratings for Avedro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avedro and related companies with MarketBeat.com's FREE daily email newsletter.